<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633304</url>
  </required_header>
  <id_info>
    <org_study_id>STP-001</org_study_id>
    <nct_id>NCT04633304</nct_id>
  </id_info>
  <brief_title>A Single Arm sTudy to Evaluate the Effectiveness of EndoAVF in a Pre-dialysis Population (STEP Study)</brief_title>
  <official_title>A Single Arm sTudy to Evaluate the Effectiveness of EndoAVF in a Pre-dialysis Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Institute of Renal Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>California Institute of Renal Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated post-marketing study that will evaluate use of the WaveLinQ&#xD;
      system, a new and novel method of fistula creation using a percutaneous method in patients&#xD;
      who require the creation of an arteriovenous fistula (AVF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This investigator-initiated post-marketing study will evaluate use of the WaveLinQ system, a&#xD;
      new and novel method of fistula creation, which uses a percutaneous method to create an AVF.&#xD;
      Thirty male and female subjects with CKD 3-5 and who are clinical indicated for arteriovenous&#xD;
      fistula (AVF) creation will be enrolled using the WaveLinQ device. Eligibility confirmation&#xD;
      will be confirmed during screening up to 28 days from the index procedure. Subjects who are&#xD;
      eligible will undergo fistula creation per standard institutional technique (index/baseline)&#xD;
      and be followed at least monthly for 6 months per their standard of care plan. Primary,&#xD;
      clinical and functional patency will be observed throughout the trial in addition to other&#xD;
      data collection points per protocol. The expected total duration of subject participation&#xD;
      from screening until the end of study is up to 7 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>primary end point</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>Interval of time from access placement until any intervention is undertaken to maintain or re-establish patency - 6 weeks</time_frame>
    <description>Successful endoAVF creation confirmed by intraprocedural angiography or duplex Ultrasound post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physiologically mature endoAVF at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Percent of patients who did not require any intervention to be undertaken to maintain or re-establish patency</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>CKD Stage 3</condition>
  <condition>CKD Stage 4</condition>
  <condition>CKD Stage 5</condition>
  <arm_group>
    <arm_group_label>AVF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm study using primary and secondary end points as comperators between subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoAVF System for endovascular AV fistula creation</intervention_name>
    <description>AV fistula creation</description>
    <arm_group_label>AVF</arm_group_label>
    <other_name>WavelinQ™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female Age of at least 18 years&#xD;
&#xD;
          2. CKD 3 through 5 as measured by GFR 45 and under by MDRD equation on two separate&#xD;
             occasions at least 3 months apart.&#xD;
&#xD;
          3. Provide written informed consent using a form that is approved by the Institutional&#xD;
             Review Board (IRB) prior to collection of study data or performance of study&#xD;
             procedures.&#xD;
&#xD;
          4. Currently not on hemodialysis.&#xD;
&#xD;
          5. Life expectancy of at least one year&#xD;
&#xD;
          6. Meets Anatomical Criteria for EndoAVF creation via pre-procedure Duplex or Venography&#xD;
             Vascular anatomy suitable for creation of the AV fistula&#xD;
&#xD;
          7. Willing to comply with the specified follow-up evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anatomical exclusion criteria met&#xD;
&#xD;
          2. Thought to need dialysis within 30 days.&#xD;
&#xD;
          3. The subject is in a hypercoagulable state.&#xD;
&#xD;
          4. The subject has known bleeding diathesis.&#xD;
&#xD;
          5. The subject has insufficient cardiac output to support a native fistula in the opinion&#xD;
             of the investigator.&#xD;
&#xD;
          6. Known history of active intravenous drug abuse.&#xD;
&#xD;
          7. The subject has a known allergy or hypersensitivity to contrast media which cannot be&#xD;
             adequately pre-medicated.&#xD;
&#xD;
          8. The subject has known adverse effects to sedation and/or anesthesia which cannot be&#xD;
             adequately pre-medicated.&#xD;
&#xD;
          9. Evidence of active infection on the day of the index procedure (temperature of ≥ 38.0°&#xD;
             Celsius and/ or WBC of ≥ 12,000 cells/ μL, if collected).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osman Khawar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Institute of Renal Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Osman Khawar, MD</last_name>
    <phone>7602943162</phone>
    <email>okhawar@bnmg.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Gastauer</last_name>
    <phone>8588108155</phone>
    <email>mgastauer@balboaunited.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92027</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Osman Khawar, MD</last_name>
      <phone>760-294-3162</phone>
      <email>okhawar@bnmg.org</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Ulloa</last_name>
      <phone>7602943162</phone>
      <email>culloa@balboaunited.org</email>
    </contact_backup>
    <investigator>
      <last_name>Osman Khawar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jones RG, Khawaja A, Tullett K, Inston NG. Early experience and observations in endovascular dialysis fistula re-intervention. J Vasc Access. 2020 Nov;21(6):818-825. doi: 10.1177/1129729819888374. Epub 2019 Dec 9. Review.</citation>
    <PMID>31814515</PMID>
  </reference>
  <reference>
    <citation>Inston N, Khawaja A, Tullett K, Jones R. WavelinQ created arteriovenous fistulas versus surgical radiocephalic arteriovenous fistulas? A single-centre observational study. J Vasc Access. 2020 Sep;21(5):646-651. doi: 10.1177/1129729819897168. Epub 2020 Jan 2.</citation>
    <PMID>31894716</PMID>
  </reference>
  <results_reference>
    <citation>Lok CE, Rajan DK, Clement J, Kiaii M, Sidhu R, Thomson K, Buldo G, Dipchand C, Moist L, Sasal J; NEAT Investigators. Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Access Trial (NEAT). Am J Kidney Dis. 2017 Oct;70(4):486-497. doi: 10.1053/j.ajkd.2017.03.026. Epub 2017 Jun 14.</citation>
    <PMID>28624422</PMID>
  </results_reference>
  <results_reference>
    <citation>Radosa CG, Radosa JC, Weiss N, Schmidt C, Werth S, Hofmockel T, Plodeck V, Gatzweiler C, Laniado M, Hoffmann RT. Endovascular Creation of an Arteriovenous Fistula (endoAVF) for Hemodialysis Access: First Results. Cardiovasc Intervent Radiol. 2017 Oct;40(10):1545-1551. doi: 10.1007/s00270-017-1750-x. Epub 2017 Aug 7.</citation>
    <PMID>28785804</PMID>
  </results_reference>
  <results_reference>
    <citation>Berland TL, Clement J, Griffin J, Westin GG, Ebner A. Endovascular Creation of Arteriovenous Fistulae for Hemodialysis Access with a 4 Fr Device: Clinical Experience from the EASE Study. Ann Vasc Surg. 2019 Oct;60:182-192. doi: 10.1016/j.avsg.2019.02.023. Epub 2019 May 8.</citation>
    <PMID>31075457</PMID>
  </results_reference>
  <results_reference>
    <citation>Zemela MS, Minami HR, Alvarez AC, Smeds MR. Real-World Usage of the WavelinQ EndoAVF System. Ann Vasc Surg. 2021 Jan;70:116-122. doi: 10.1016/j.avsg.2020.05.006. Epub 2020 May 15.</citation>
    <PMID>32417285</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

